KRN5500: Additional Phase IIa data

A subset analysis of 17 patients with chemotherapy-induced peripheral neuropathy (CIPN) from a double-blind, dose-escalation, U.S. Phase IIa trial showed that KRN5500 significantly reduced neuropathic pain by 27% from baseline when measured as best response to treatment regardless of dose or timing vs. 0% for placebo (p=0.03). KRN5500 non-significantly reduced neuropathic pain by 16% when measured as best response within 7 days of the last treatment given vs. 0% for placebo (p=0.19). Data were presented at the World Congress on Pain in Montreal. ...